Immunoliposomes directed against multiple tumor antigens, for example, EGFR and VCAM-1 could, increase the therapeutic efficacy and, hereby, immunoliposomal therapy could become clinically significant as a novel treatment for cancer. This evidence concerns the gene VCAM1 and neoplasm.